Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1 5Phase 3 4Phase 1/2 2Phase 4 1Phase 2/3 1

Status

Active not recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Thoracic 2Gastrointestinal 2Other solid neoplasm 1Head & Neck 1

Conditions

Ovarian Neoplasms 3Neoplasm Metastasis 1Endometrial Neoplasms 1

Interventions

Paclitaxel 150Carboplatin 110Cisplatin 95Bevacizumab 42Topotecan 39Gemcitabine 38liposomal doxorubicin 34Radiotherapy 29Doxorubicin 27Brachytherapy 26Taxes 24pembrolizumab 20olaparib 20Drug Therapy 20Hyperthermic Intraperitoneal Chemotherapy 16Chemotherapy, Adjuvant 16human papillomavirus vaccine, L1 type 16, 18 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14Docetaxel 13Neoadjuvant Therapy 12Platinum 10niraparib 9Radiation 91,2-diaminocyclohexaneplatinum II citrate 9Vaccines, Synthetic 8Surgical Procedures, Operative 8atezolizumab 7Specimen Handling 7Papillomavirus Vaccines 7Letrozole 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × dostarlimab × Gynecologic × Clear all
NCT03602859 2025-12-31

FIRST

Tesaro, Inc.

Phase 3 Active not recruiting
1,400 enrolled 18 charts
Gynecologic

Ovarian Neoplasms

NCT05201547 2025-12-04

DOMENICA

ARCAGY/ GINECO GROUP

Phase 3 Active not recruiting
260 enrolled
Gynecologic

Neoplasm Metastasis, Endometrial Neoplasms

NCT04679064 2021-08-27

NItCHE-MITO33

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 3 Unknown
427 enrolled
Gynecologic

Ovarian Neoplasms

NCT03806049 2021-07-15

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Phase 3 Withdrawn
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡